DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
A phase 2/3 trial of Disitamab vedotin and Cadonilimab in gastric & gastro-oesophageal junction cancer, run by RemeGen Co., Ltd., now recruiting.
Overview
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy is a phase 2/3 interventional study registered as NCT06221748 by RemeGen Co., Ltd., with 90 participants planned, started 2024-02-22 and due to reach its primary completion in 2026-12. Interventions recorded: Disitamab Vedotin Injection, Cadonilimab Injection and Paclitaxel Injection.
Similar pages
not linked directly; found by shared links- TrialTo Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
Shares RemeGen, Disitamab vedotin and the tag pipeline.
- TrialA Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialPerioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Shares Cadonilimab, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialDV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
Shares RemeGen, Disitamab vedotin and the tag pipeline.
- TrialEfficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
Shares RemeGen, Disitamab vedotin and the tag pipeline.
- TrialNeoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
Shares RemeGen, Disitamab vedotin and the tag pipeline.